Aled Williams
Directeur/Membre du Conseil chez DESTINY PHARMA PLC
Fortune : 11 113 $ au 30/04/2024
Profil
Aled Paton Williams is currently an Independent Non-Executive Director at Destiny Pharma Plc and a Vice President-Global Strategy at Shire Pharmaceuticals Ltd.
Previously, he served as the Chief Executive Officer at Enthera Srl from 2022 to 2024, the Chief Business Officer at Polyneuron Pharmaceuticals AG from 2020 to 2022, and the Chief Commercial Officer at VectivBio AG from 2019 to 2020.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DESTINY PHARMA PLC
0,05% | 25/05/2023 | 50 000 ( 0,05% ) | 11 113 $ | 30/04/2024 |
Postes actifs de Aled Williams
| Sociétés | Poste | Début |
|---|---|---|
| DESTINY PHARMA PLC | Directeur/Membre du Conseil | 01/06/2022 |
Shire Pharmaceuticals Ltd.
 Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceuticals Ltd. is a patient-focused, British innovation-driven pharmaceutical company. The private company is based in London, UK. Takeda has a distinguished 240-year history and aspires to bring better health and a brighter future for people worldwide. Shire Pharmaceuticals was founded in 1986. The CEO is Flemming Ørnskov. | Corporate Officer/Principal | - |
Anciens postes connus de Aled Williams
| Sociétés | Poste | Fin |
|---|---|---|
Enthera Srl
 Enthera Srl BiotechnologyHealth Technology Enthera Srl develops therapeutic solutions to treat diabetes. The company was founded in 1985 by in October 2016 by Maria Gabriella Camboni, Paolo Fiorina and Francesca D'Addio and is headquartered in Milan, Italy. | Directeur Général | 23/01/2024 |
Polyneuron Pharmaceuticals AG
 Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/04/2022 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/09/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DESTINY PHARMA PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
Polyneuron Pharmaceuticals AG
Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Enthera Srl
Enthera Srl BiotechnologyHealth Technology Enthera Srl develops therapeutic solutions to treat diabetes. The company was founded in 1985 by in October 2016 by Maria Gabriella Camboni, Paolo Fiorina and Francesca D'Addio and is headquartered in Milan, Italy. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Shire Pharmaceuticals Ltd.
Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceuticals Ltd. is a patient-focused, British innovation-driven pharmaceutical company. The private company is based in London, UK. Takeda has a distinguished 240-year history and aspires to bring better health and a brighter future for people worldwide. Shire Pharmaceuticals was founded in 1986. The CEO is Flemming Ørnskov. | Health Technology |
